Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3002 in Atopic Dermatitis
NCT07399067Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IBI3002 in atopic dermatitis (AD), sponsored by Innovent Biologics. Primary endpoint: Eczema Area and Severity Index at 16 weeks. Started Feb 2026; status: recruiting.
02
Drugs
IBI3002
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07399067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399067.